Overcoming Regulatory Challenges In 3D Printing of Pharmaceuticals
Updated: May 31
What are the regulatory challenges faced by the 3D printing of pharmaceuticals, and how do we overcome them? There is no denying that the future of individualized or customized medications is a significant factor in the growing popularity of 3D-printed pharmaceuticals.
Some of the benefits of 3D-printed pharmaceuticals and why they're becoming so attractive to manufacturing companies include the more straightforward production process, the ability to customize compositions of pharmaceuticals, customized active pharmaceutical ingredient (API) release profiles, and customized therapeutic applications.
It's only the beginning of 3D printing technology in the pharmaceutical industry. However, market research suggests that the 3D-printed pharmaceutical industry is expected to grow by as much as 6% annually in the coming years.
As an industry leader in the 3D printing of pharmaceutical products, Laxxon Medical has uniquely positioned itself as an innovator in the field of 3D printing thanks to its SPID®-Technology.
However, what are some of the regulatory challenges that are being faced by the 3D printing of pharmaceuticals, and how do we overcome them?
Regulatory Challenges In the 3D Printing of Pharmaceuticals
As we continue to see improvements in 3D printing technology, it becomes both more reliable and affordable. However, not everyone can just start 3D printing pharmaceutical products, and there are strict regulations in place to govern how pharmaceutical products are produced.